Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Smart 3: Golcadomide, Glofitamab, Polatuzumab Vedotin, and Obinutuzumab in Newly Diagnosed Large B-Cell Lymphoma
NCT07917832Phase 2Not yet recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Apr 2027
- Primary completion
- Jun 2027
- Countries
- 1
01
Overview
Phase 2, open-label trial of golcadomide, glofitamab and polatuzumab vedotin in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Safety and adverse events, Overall Response Rate and 1 more. Planned start Apr 2027; status: not yet recruiting.
02
Drugs
golcadomideglofitamabpolatuzumab vedotin
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT07917832.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07917832.